The cell therapy manufacturing market is estimated to reach close to USD 11 Billion by 2030 (Roots Analysis)

Author : kevin987

Publish Date : 2021-04-07 06:29:02

The cell therapy manufacturing market is estimated to reach close to USD 11 Billion by 2030 (Roots Analysis)

Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers

Roots Analysis is pleased to announce the publication of its recent study, titled, “Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030”.”

The report features an extensive study of the current market landscape and future opportunities associated with cell therapy manufacturing. It focuses on both contract manufacturers, as well as developers with in-house manufacturing facilities, offering in-depth analyses of the various business entities that are engaged in this domain, across different global regions. Amongst other elements, the report includes:

An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective cell therapy manufacturing capabilities, over the period 2015-2019.
An analysis of the recent partnerships focused on the manufacturing of cell-based therapies, which have been established in the period 2014-2019.
Informed estimates of the annual commercial and clinical demand for cell therapies, in terms of number of cells produced and area dedicated to manufacturing.
An estimate of the overall, installed capacity for manufacturing cell-based therapies based on information reported by industry stakeholders in the public domain A competitiveness analysis of biological targets, featuring insightful pictorial summaries and representations.
A detailed analysis of the various factors that are likely to influence the pricing of cell-based therapies, featuring different models / approaches that may be adopted by manufacturers while deciding the prices of their proprietary offerings.
A qualitative analysis, highlighting the various factors that need to be taken into consideration by cell therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
An elaborate discussion on the role of automation technologies in improving current manufacturing methods.
A discussion on cell therapy manufacturing regulations across various geographies, including North America, Europe, and Asia Pacific.
Elaborate profiles of key players (industry and non-industry) that offer contract manufacturing services.
A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry’s evolution, under a comprehensive SWOT framework.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
More than 100 industry players and over 60 non-industry players currently claim to manufacture different types of cell therapies, either for in-house requirements or on contract basis
The market is fragmented, featuring both established players and new entrants, which claim to operate at various scales and manufacture a diverse range of cell therapies
In order to cater to the growing needs of clients / sponsors, companies have established presence across different regions; presently, the US, the UK and China are the key hubs for cell therapy manufacturing
In recent years, a significant increase in partnership activity has been observed in this domain; in fact, therapy developers have already inked manufacturing deals with both indigenous and international experts
In order to enhance core competencies related to the domain, both drug developers and CMOs are actively investing in expanding their existing infrastructure and capabilities
Cell therapy manufacturers are also gradually opting to automate various operations in the supply chain; the primary objective is to achieve favorable bench-to-clinic timelines and cut down on production related losses
Currently, the installed global capacity for cell therapy manufacturing is estimated to be spread across 1.2+ million square feet of dedicated cleanroom area distributed across various scales of operation
More than 70,000 patients were estimated to have been enrolled in cell therapy related clinical trials; the demand for cell therapies is anticipated to grow significantly over the next decade
Revenues from manufacturing operations of T-cell therapies are anticipated to capture higher market share; the benefit will be realized by both autologous and allogeneic therapies across different regions the world

Type of therapy
T-cell therapies (CAR-T therapies, TCR therapies, TIL therapies)
Dendritic cell therapies
Tumor cell therapies
NK cell therapies
Stem cell therapies

Source of cells

Autologous
Allogeneic

Scale of operation

Clinical
Commercial

Purpose of manufacturing

Contract manufacturing
In-house manufacturing

Key geographical regions
North America
Europe
Asia Pacific
Rest of the world

Key companies covered in the report

BioNTech Innovative Manufacturing Services
Cell Therapies
Cell and Gene Therapy Catapult
Center for Cell and Gene Therapy, Baylor College of Medicine
Centre for Cell Manufacturing Ireland, National University of Ireland
Clinical Cell and Vaccine Production Facility, University of Pennsylvania
Cognate BioServices
FUJIFILM
Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital
Hitachi Chemical
KBI Biopharma
Laboratory for Cell and Gene Medicine, Stanford University
Lonza
MaSTherCell
MEDINET
Molecular and Cellular Therapeutics, University of Minnesota
Newcastle Cellular Therapies Facility, Newcastle University
Nikon CeLL innovation
Rayne Cell Therapy Suite, King’s College London
Roslin Cell Therapies
Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
Sydney Cell and Gene Therapy
WuXi Advanced Therapies